Cantor Fitzgerald L. P. Has $465,000 Stock Position in Trevi Therapeutics, Inc. $TRVI

Cantor Fitzgerald L. P. reduced its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 49.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,861 shares of the company’s stock after selling 49,140 shares during the period. Cantor Fitzgerald L. P.’s holdings in Trevi Therapeutics were worth $465,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its stake in Trevi Therapeutics by 4.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company’s stock worth $195,000 after purchasing an additional 911 shares during the period. Ameritas Investment Partners Inc. raised its stake in Trevi Therapeutics by 20.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company’s stock valued at $70,000 after purchasing an additional 1,300 shares during the period. Persistent Asset Partners Ltd lifted its holdings in shares of Trevi Therapeutics by 3.3% in the second quarter. Persistent Asset Partners Ltd now owns 42,788 shares of the company’s stock valued at $234,000 after purchasing an additional 1,384 shares in the last quarter. BIT Capital GmbH lifted its holdings in shares of Trevi Therapeutics by 32.0% in the third quarter. BIT Capital GmbH now owns 6,739 shares of the company’s stock valued at $62,000 after purchasing an additional 1,633 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Trevi Therapeutics by 20.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 12,000 shares of the company’s stock worth $66,000 after buying an additional 2,000 shares during the period. Institutional investors and hedge funds own 95.76% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on TRVI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, January 21st. Stifel Nicolaus raised their price objective on Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research note on Monday, March 9th. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Finally, D. Boral Capital reissued a “buy” rating and issued a $19.00 price target on shares of Trevi Therapeutics in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $21.10.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $11.01 on Monday. The business’s 50-day moving average price is $11.17 and its two-hundred day moving average price is $10.87. Trevi Therapeutics, Inc. has a one year low of $4.85 and a one year high of $14.39. The company has a market capitalization of $1.41 billion, a P/E ratio of -29.76 and a beta of 0.94.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.